Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
ADCT-701 for Rare Cancers
Recruiting1 awardPhase 1
Bethesda, Maryland
This trial tests a new drug for adults with rare cancers in the digestive system, pancreas, lungs, and other parts of the body. Participants will have tests and receive the drug every 21 days for up to 2 years, with follow-up for up to 5 years.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service